Fractional flow in PCI
This article was originally published in The Gray Sheet
Executive Summary
Evidence strongly suggests that angiography guided by intravascular fractional flow reserve (FFR) measurement improves outcomes in patients undergoing percutaneous coronary intervention compared to angiography alone, according to new practice guidelines from the American College of Cardiology, American Heart Association and Society for Cardiac Angiography and Interventions. The updated ACC/AHA/SCAI guidelines, published in the December issue of Circulation, elevate the level of evidence supporting FFR from Class IIa, Level B to Class IIa, Level A. FFR uses a sensor on a guidewire to measure the range of pressure across a coronary lesion to assess its severity, allowing clinicians to better decide which lesions to stent. The new guidelines cited the 2009 FAME study, showing multivessel PCI guided by FFR reduced deaths and heart attacks (1"The Gray Sheet" Oct. 5, 2009). FFR product maker Volcano (PrimeWire, FloWire and ComboWire XT) says the new guidelines should boost physician use of the procedure
You may also be interested in...
Volcano Takes Advantage Of Competitors' Trials To Tout FFR, IVUS
Intravascular imaging device-maker Volcano is talking up the results of two trials presented at the TCT conference, although it was not the primary sponsor of either of them
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.